Kiniksa Pharmaceuticals, Ltd. (KNSA)
$15.53
Rating:
Recommendation:
-
| Symbol | KNSA |
|---|---|
| Price | $15.53 |
| Beta | -0.094 |
| Volume Avg. | 0.48M |
| Market Cap | 1.090B |
| Shares () | - |
| 52 Week Range | 10.29-20.65 |
| 1y Target Est | - |
| DCF Unlevered | KNSA DCF -> | |
|---|---|---|
| DCF Levered | KNSA LDCF -> | |
| ROE | -46.67% | Strong Sell |
| ROA | -55.50% | Strong Sell |
| Operating Margin | - | |
| Debt / Equity | -2.76% | Neutral |
| P/E | 4.79 | Buy |
| P/B | -2.22 | Strong Sell |
Latest KNSA news
About
Download (Excel)Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, which is in Phase 2a clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. Kiniksa Pharmaceuticals, Ltd. was incorporated in 2015 and is based in Hamilton, Bermuda.